[New drug approval: Lisocabtagene maraleucel for patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B after two or more lines of systemic treatment]

Bull Cancer. 2022 Sep;109(9):879-880. doi: 10.1016/j.bulcan.2022.04.020. Epub 2022 Jun 15.
[Article in French]
No abstract available

Keywords: CAR-T cell; Diffuse large B-cell lymphoma; Lisocabtagene maraleucel; Lymphome B diffus à grandes cellules; Rechute; Relapse.

Publication types

  • Letter

MeSH terms

  • Drug Approval
  • Humans
  • Immunotherapy, Adoptive / adverse effects
  • Lymphoma, Follicular* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Lymphoma, Non-Hodgkin* / drug therapy